How Strong Are Omeros’ Chances for Approval of Its New Monoclonal Antibody?
Omeros’ monoclonal antibody narsoplimab shows promising signals in rare complement‑mediated diseases, but approval hinges on larger controlled data, safety, and regulator feedback.
Yahoo Finance
2 min read
Stocks
Biotech
Market Analysis